CRISPR Therapeutics (CRSP) vs Relay Therapeutics (RLAY)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Relay Therapeutics (RLAY) has outperformed CRISPR Therapeutics (CRSP) over the past year, gaining 184.9% versus a loss of 34.3%. Over five years, CRSP leads with a -48.0% price change compared with -49.0% for RLAY. CRISPR Therapeutics is the larger company by market cap ($4.88 billion vs $3.82 billion), about 1.3 times the size, while Relay Therapeutics is growing revenue faster (+53.4% vs -90.6%).
Relay Therapeutics converts more of its revenue into profit, with a net margin of -1800.6% versus -16569.8%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CRSP | RLAY |
|---|---|---|
| Share price | $50.44 | $17.41 |
| Market cap | $4.88B | $3.82B |
| 1-day change | -3.65% | -3.01% |
| YTD return | -3.81% | +105.79% |
| 1-year return | -34.31% | +184.94% |
| 5-year return | -48.00% | -48.96% |
| EPS (TTM) | $-4.74 | $-1.56 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $3.51M | $15.36M |
| Revenue growth (YoY) | -90.59% | +53.44% |
| Net income (latest FY) | $-581.60M | $-276.48M |
| Operating margin | -18933.65% | -1971.59% |
| Net margin | -16569.77% | -1800.58% |
| 52-week high | $78.00 | $21.27 |
| 52-week low | $44.12 | $5.85 |
| Distance from 52-week high | -35.33% | -18.15% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | +73.59% | +58.41% |
| Average volume | 1.62M | 2.80M |
| Shares outstanding | 96.69M | 219.14M |
| Employees | — | 202 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- RLAY has outperformed CRSP by 219.2 percentage points over the past year.
- Relay Therapeutics is more profitable, keeping -1800.6 cents of every revenue dollar as net income versus -16569.8 cents for CRISPR Therapeutics.
- Relay Therapeutics grew revenue faster in its latest fiscal year (+53.44% vs -90.59%).
About CRISPR Therapeutics
CRSP stock →CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious human diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. The company's CRISPR/Cas9 is a technology for gene editing which is the process of precisely altering specific sequences of genomic DNA.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances)
About Relay Therapeutics
RLAY stock →Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 202 employees
CRSP vs RLAY FAQ
Which is bigger, CRISPR Therapeutics or Relay Therapeutics?
CRISPR Therapeutics (CRSP) is larger, with a market capitalization of $4.88B compared with $3.82B for Relay Therapeutics (RLAY).
Which stock has performed better over the past year, CRSP or RLAY?
RLAY returned +184.94% over the past 12 months, compared with -34.31% for CRSP (price return, excluding dividends). Past performance does not predict future results.
Are CRISPR Therapeutics and Relay Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.